NANJING, China, April 28 /PRNewswire-FirstCall/ -- Simcere Pharmaceutical Group (NYSE:SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today announced its participation in Credit Suisse's 3rd Annual Healthcare Trip, to be held May 6-10 and May 19-25 in Shenzhen, Shanghai, Beijing and Weihai.
Simcere senior management will give a presentation at the Grand Hyatt Shanghai on Wednesday, May 7, 2008, from 10:10 a.m. to 11:10 a.m. Beijing/Hong Kong time.
A copy of Simcere's investor presentation will be available on the investor relations portion of the Company's Web site, located at http://www.simcere.com/.
About Simcere Pharmaceutical Group Simcere Pharmaceutical Group (NYSE:SCRNYSE:Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication, and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases, and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com/.
For investor and media inquiries, please contact:
Email: In Nanjing:
Frank Zhao
Chief Financial Officer
Simcere Pharmaceutical Group
Tel: 86-25-8556-6666 ext 8818 In Beijing:
Wu Kejia
Brunswick Group
Tel: 86-10-6566-2256 In Hong Kong
Joseph Lo
Brunswick Group
Tel: 852-3512-5000 In the United States:
Michael Guerin
Brunswick Group LLC
Tel: +1-212-333-3810
DATASOURCE: Simcere Pharmaceutical Group CONTACT: In Nanjing, Frank Zhao, Chief Financial Officer of Simcere Pharmaceutical Group +86-25-8556-6666 ext 8818; or in Beijing, Wu Kejia, Brunswick Group, +86-10-6566-2256, or in Hong Kong, Joseph Lo, Brunswick Group, +852-3512-5000, or in the United States, Michael Guerin, Brunswick Group LLC, +1-212-333-3810, all for Simcere Pharmaceutical Group Web site: http://www.simcere.com/
|